Triglyceride-glucose index and triglyceride-glucose–body mass index as prognostic factors for early stage breast cancer patients receiving neoadjuvant chemotherapy

作者：Fucheng Li, Tian Gao, Zhaoting Li, He Dou, Yuling Ba, Siyuan Jia, Danli Luo, Min Xiao · 发表于：Translational Oncology · 年份：2025 · DOI：10.1016/j.tranon.2025.102292 · 被引用次数：8 · 研究领域：Cancer Risks and Factors、Metabolism, Diabetes, and Cancer、Cancer, Lipids, and Metabolism

BACKGROUND: Insulin resistance (IR) is closely associated with the risk of breast cancer. The triglyceride-glucose (TyG) index and the triglyceride-glucose-body mass index (TyG-BMI) are considered surrogate indicators of IR; however, their prognostic value in breast cancer patients has not been discussed. The purpose of this study is not only to explore whether the TyG index and the TyG-BMI can predict the chemotherapy response and long-term prognosis of breast cancer patients receiving neoadjuvant chemotherapy (NACT) but also to investigate the possible mediating mechanism and to analyze the relationship between TyG-related enzyme expression and drug resistance and prognosis. METHODS: From November 2011 to December 2018, a total of 335 breast cancer patients referred to Harbin Medical University Cancer Hospital who received NACT and surgery were registered in this retrospective study. The TyG index and TyG-BMI before the first chemotherapy were retrospectively calculated. Tissue samples of breast cancer patients were obtained from the Cancer Genome Atlas database, and the associations between the expression levels of the FBP1 and G6PD enzymes and the clinicopathological features and prognosis of breast cancer were analyzed. RESULTS: In receiver operating characteristic analyses, the optimal cutoff values for the TyG and TyG-BMI were determined at 8.01 and 194.91, respectively. Low levels of the TyG and TyG-BMI were not associated with pathological complete response. In multi...